Benefits to Participating Practices

Enhanced Patient Outcomes

VADA streamlines practice operations, leading to improved patient care.

Financial Gains

Even at the lowest participation level, practices can generate an additional $10,000 per month in EBITDA.
Higher levels of VADA execution can increase revenue by $50,000 or more per month, with nearly all of it translating to EBITDA. Participation beyond the basic level is optional.
Every location is guaranteed $100,000 in increased revenue over the first 12 months or IDMA will pay the difference between the $100,000 and what is collected.

Profit Sharing from VADA’s Sale

Upon VADA’s successful sale, participating doctors will receive a share of Medical Synergy’s proceeds based on pre-established agreements.

CAN A PARTICIPATING PRACTICE SELL AS A RESULT OF BEING INVOLVED IN THIS PROGRAM?

Yes, but selling is not required. Practices can simply track their valuation increases using the HPS dashboard.

If a practice chooses to sell, it must submit documentation to HPS for their practice profile creation. Once completed, the practice will be anonymously listed on the HPS platform. Offers will then be displayed on the dentist's own personal dashboard which is the same dashboard used to track the amount of increased EBITDA and VADA’s impact on valuation.

HOW DOES VADA INCREASE PRACTICE VALUATION?

The core idea is that ancillary-based EBITDA is more attractive to buyers than provider-dependent EBITDA.

Provider-dependent EBITDA is often affected by inflation, high staffing costs, and can significantly decline if a provider leaves the practice. In contrast, ancillary-based EBITDA requires minimal overhead and remains stable even after a provider’s departure, ensuring long-term financial stability.

HPS’s platform includes over 1,400 buyers actively seeking healthcare practices, many of whom prioritize ancillary EBITDA models. These buyers are willing to pay a premium for practices with strong ancillary revenue streams.

By incorporating VADA, dental professionals can enhance patient outcomes, increase practice valuation, share in the proceeds of the sale of VADA as an entity and unlock new financial opportunities—all with seamless support from Medical Synergy, IDMA, and HPS.